Jordan Berlin

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. doi request reprint A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Jordan Berlin
    Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
    Clin Cancer Res 19:258-67. 2013
  2. pmc Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation
    Kevin Vo
    College of Pharmacy, The University of Tennessee, Memphis, TN, USA
    Mol Cancer 10:138. 2011
  3. doi request reprint Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma
    Jordan D Berlin
    Vanderbilt University Medical Center, Nashville, TN 37232 6307, USA
    Clin Colorectal Cancer 7:44-7. 2008
  4. ncbi request reprint Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer
    Jordan Berlin
    Vanderbilt University Medical Center, Nashville, TN 37232 6307, USA
    Clin Colorectal Cancer 6:427-32. 2007
  5. ncbi request reprint Chemotherapeutic advances in pancreatic cancer
    Jordan D Berlin
    Division of Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Curr Oncol Rep 5:219-26. 2003
  6. ncbi request reprint Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer
    Dong W Kim
    Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Int J Radiat Oncol Biol Phys 67:397-404. 2007
  7. pmc Aflibercept
    Kristen K Ciombor
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232, USA
    Clin Cancer Res 19:1920-5. 2013
  8. ncbi request reprint A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas
    Karen L Tedesco
    Department of Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Radiother Oncol 76:54-8. 2005
  9. doi request reprint A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas
    Emily Chan
    Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
    Invest New Drugs 26:241-7. 2008
  10. doi request reprint Current treatment options for pancreatic carcinoma
    Emily Castellanos
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    Curr Oncol Rep 13:195-205. 2011

Research Grants

Collaborators

Detail Information

Publications41

  1. doi request reprint A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Jordan Berlin
    Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
    Clin Cancer Res 19:258-67. 2013
    ..The primary endpoint was progression-free survival (PFS). Key secondary objectives included evaluation of predictive biomarkers and pharmacokinetic drug interactions...
  2. pmc Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation
    Kevin Vo
    College of Pharmacy, The University of Tennessee, Memphis, TN, USA
    Mol Cancer 10:138. 2011
    ..The mounting evidence supporting a role for Notch in cancer promotion and survival suggests that targeting this pathway alone or in combination with other therapeutics represents a promising therapeutic strategy...
  3. doi request reprint Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma
    Jordan D Berlin
    Vanderbilt University Medical Center, Nashville, TN 37232 6307, USA
    Clin Colorectal Cancer 7:44-7. 2008
    ....
  4. ncbi request reprint Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer
    Jordan Berlin
    Vanderbilt University Medical Center, Nashville, TN 37232 6307, USA
    Clin Colorectal Cancer 6:427-32. 2007
    ..We conducted this phase II study to assess the ability of panitumumab to be administered with first-line irinotecan-containing regimens in patients with mCRC...
  5. ncbi request reprint Chemotherapeutic advances in pancreatic cancer
    Jordan D Berlin
    Division of Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Curr Oncol Rep 5:219-26. 2003
    ..Although matrix metalloproteinase inhibitors and farnesyl transferase inhibitors did not appear to be effective in initial studies, other targeted therapies are beginning to enter clinical trials...
  6. ncbi request reprint Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer
    Dong W Kim
    Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Int J Radiat Oncol Biol Phys 67:397-404. 2007
    ..We evaluated paclitaxel-based induction chemoradiotherapy in patients with localized esophageal cancer to determine its feasibility, clinical response, pathologic response, and overall survival...
  7. pmc Aflibercept
    Kristen K Ciombor
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232, USA
    Clin Cancer Res 19:1920-5. 2013
    ..Optimal strategies for incorporating aflibercept into treatment regimens that include other anti-VEGF and cytotoxic chemotherapeutic agents, as well as development of predictive biomarkers for treatment response, have yet to be defined...
  8. ncbi request reprint A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas
    Karen L Tedesco
    Department of Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Radiother Oncol 76:54-8. 2005
    ..We conducted a phase I study to assess the toxicity and determine the maximum tolerated dose of 9NC when combined with radiation in patients with locally advanced adenocarcinoma of the pancreas...
  9. doi request reprint A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas
    Emily Chan
    Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
    Invest New Drugs 26:241-7. 2008
    ..Based on pre-clinical data, the combination of CEP-701, an inhibitor of tyrosine kinases including Flt-3, TRK-A/B and JCK-2, with gemcitabine appeared promising...
  10. doi request reprint Current treatment options for pancreatic carcinoma
    Emily Castellanos
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    Curr Oncol Rep 13:195-205. 2011
    ..This article reviews current strategies in the diagnosis and treatment of resectable and advanced pancreas cancer...
  11. pmc Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USA
    N Engl J Med 358:1109-17. 2008
    ..A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States...
  12. doi request reprint Neuroendocrine carcinoma in an adolescent with hypercortisolemia
    Emily L Fagan
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Pediatr Hematol Oncol 34:e117-9. 2012
    ..The patient died 9 months after diagnosis. Autopsy revealed disseminated neuroendocrine carcinoma. The rarity of this tumor compels a cooperative investigational model involving pediatric and adult oncologists...
  13. ncbi request reprint Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer
    Vicki L Keedy
    Vanderbilt University Medical Center, 777 Preston Research Building, Nashville, TN 37232, USA
    Curr Treat Options Oncol 7:381-8. 2006
    ....
  14. ncbi request reprint The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study
    Kenneth R Hande
    Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA
    Clin Cancer Res 12:2834-40. 2006
    ..ABT-751 was investigated in this phase 1 trial designed to assess its maximum tolerated dose (MTD), dose-limiting toxicity (DLT), tolerability, and pharmacokinetics...
  15. ncbi request reprint Anti-angiogenic treatment of gastrointestinal malignancies
    J Stuart Salmon
    Vanderbilt University Medical Center, Division of Hematology Oncology, Nashville, TN 37232 6307, USA
    Cancer Invest 23:712-26. 2005
    ..This review will examine the preclinical foundation and then focus on the clinical studies of anti-VEGF therapy in gastrointestinal cancers...
  16. ncbi request reprint Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer
    Karen L Tedesco
    Department of Oncology, Vanderbilt University School of Medicine and Veteran s Affairs Medical Center, Nashville, TN, USA
    Int J Radiat Oncol Biol Phys 61:1364-70. 2005
    ..This Phase I study was designed to determine the maximal tolerated dose and dose-limiting toxicity of UFT, leucovorin, and cisplatin when given with radiotherapy in the neoadjuvant treatment of resectable esophageal cancer...
  17. pmc Aurora kinase inhibitors--rising stars in cancer therapeutics?
    Altaf A Dar
    Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, 1255 Light Hall, 2215 Garland Avenue, Nashville, TN 37232, USA
    Mol Cancer Ther 9:268-78. 2010
    ..Over the past several years, Aurora kinases have become attractive targets. Several ongoing clinical trials and bench-based research are assessing the unique therapeutic potential of Aurora-based targeted therapy...
  18. ncbi request reprint Ethics in oncology: consulting for the investment industry
    Jordan Berlin
    Vanderbilt University Medical Center, Nashville, TN, USA
    J Clin Oncol 25:444-6. 2007
    ..Because these columns are intended to address the concerns of ASCO members, the Committee welcomes suggestions for future topics at vignettes@asco.org. Martin D. Abeloff, MD, Chair, Ethics Committee...
  19. doi request reprint Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum
    Mary Kay Washington
    Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232 2561, USA
    Arch Pathol Lab Med 132:1182-93. 2008
  20. ncbi request reprint Use of percutaneous drainage to treat hepatic abscess after radiofrequency ablation of metastatic pancreatic adenocarcinoma
    K Tyson Thomas
    Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, Tennessee 37232 4753, USA
    Am Surg 70:496-9. 2004
    ..However, the incidence of hepatic abscess is increased due to bilioenteric anastomosis; extended antibiotic prophylaxis should be considered...
  21. ncbi request reprint Diagnosis and treatment of cholangiocarcinoma
    Christopher D Anderson
    Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232 4753, USA
    Oncologist 9:43-57. 2004
    ..The prognosis for unresectable patients is poor, and palliative measures should be aimed at increasing quality of life first and increasing survival second...
  22. ncbi request reprint Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
    Mace L Rothenberg
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    J Clin Oncol 21:2059-69. 2003
    ..In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)...
  23. ncbi request reprint Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?
    Mace L Rothenberg
    J Clin Oncol 21:3716-7. 2003
  24. ncbi request reprint Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    Invest New Drugs 20:377-82. 2002
    ..The objectives of this trial were to assess the maximal tolerated dose and toxicity of the combination of oral eniluracil and 5-fluorouracil and intravenous gemcitabine...
  25. ncbi request reprint Targeting vascular endothelial growth factor in colorectal cancer
    Jordan D Berlin
    Vanderbilt Medical Center, Nashville, Tennessee, USA
    Oncology (Williston Park) 16:13-5. 2002
    ..SU5416 is also being tested in a phase I/II trial combined with IFL. This article briefly reviews preclinical and clinical data leading to the current trials of these two agents in patients with colorectal cancer...
  26. doi request reprint A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies
    Laura W Goff
    Vanderbilt University, Nashville, TN 37232, USA
    Am J Clin Oncol 31:413-6. 2008
    ..This phase I study was conducted to evaluate the combination of irinotecan, a topoisomerase I inhibitor, with epirubicin, a topoisomerase II inhibitor, when administered sequentially on a once-every-three week basis...
  27. ncbi request reprint Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
    Jordan D Berlin
    Vanderbilt University, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    J Clin Oncol 20:3270-5. 2002
    ....
  28. ncbi request reprint Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer
    Daniel G Stover
    Vanderbilt University School of Medicine, Nashville, TN, USA
    Invest New Drugs 26:339-45. 2008
    ..To identify the maximum tolerated dose (MTD) and describe dose-limiting toxicities (DLT) of pemetrexed and oxaliplatin given on a once-every-2-week schedule in patients with metastatic cancer...
  29. ncbi request reprint A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors
    A Craig Lockhart
    Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA
    Clin Cancer Res 10:468-75. 2004
    ..v. infusion...
  30. ncbi request reprint Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group
    Robert C Shepard
    University of Virginia, Charlottesville, VA, USA
    Oncology 66:303-9. 2004
    ..This trial was designed to determine if the addition of docetaxel to gemcitabine therapy produced responses in >/=25% of patients with chemonaive advanced pancreatic cancer...
  31. ncbi request reprint Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
    Mace L Rothenberg
    Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
    J Clin Oncol 23:9265-74. 2005
    ..Serial serum samples were measured for amphiregulin and transforming growth factor-alpha (TGFalpha)...
  32. ncbi request reprint Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer
    Albert Craig Lockhart
    Vanderbilt University Medical Center, Nashville, TN, USA
    Am J Clin Oncol 29:109-15. 2006
    ....
  33. ncbi request reprint The epidermal growth factor receptor as a target for colorectal cancer therapy
    A Craig Lockhart
    Department of Medicine, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
    Semin Oncol 32:52-60. 2005
    ..The role of the EGFR axis in colorectal cancer formation and progression is reviewed and the clinical development of these anticancer EGFR-targeted drugs is reviewed and updated...
  34. ncbi request reprint The epidermal growth factor receptor as a target for gastrointestinal cancer therapy
    Karen L Tedesco
    Vanderbilt University Medical Center, 777 Preston Research Building, Nashville, TN 37232, USA
    Curr Treat Options Oncol 5:393-403. 2004
    ..Data on clinical applications of these agents in GI malignancies will be the focus of this paper...
  35. ncbi request reprint A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Oncology 69:130-4. 2005
    ..The aim of this study was to evaluate the overall response rate, toxicity and overall survival in patients with locally advanced or metastatic esophageal cancer treated with gemcitabine, 5-fluorouracil (5-FU) and leucovorin...
  36. ncbi request reprint Adjuvant therapy for pancreatic cancer: to treat or not to treat?
    Jordan D Berlin
    Vanderbilt Ingram Cancer Center, Vanderbilt University, Department of Medicine, Nashville, Tennessee, USA
    Oncology (Williston Park) 21:712-8; discussion 720, 725-6, 730. 2007
    ..This review will discuss the data available from reported trials of adjuvant and neoadjuvant therapy in pancreatic cancer, address the issues leading to the ongoing controversies, and consider future directions for clinical trials...
  37. ncbi request reprint High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
    BERT H O'NEIL
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    J Clin Oncol 25:3644-8. 2007
    ....
  38. ncbi request reprint Current and future strategies for treating metastatic pancreatic cancer
    Jordan D Berlin
    Gastrointestinal Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, USA
    Clin Adv Hematol Oncol 2:510-2. 2004
  39. ncbi request reprint Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer
    Howard S Hochster
    Department of Medicine Clinical Pharmacology, New York University Cancer Institute, New York, New York, USA
    Cancer 107:676-85. 2006
    ..Other targeted therapies also are considered for future clinical trials. Based on a comprehensive review of past trials, a consensus on endpoints in the treatment of pancreatic cancer and an approach to new trials is presented...
  40. ncbi request reprint Treatment for pancreatic cancer: current therapy and continued progress
    A Craig Lockhart
    Department of Medicine, Division of Hematology Oncology, Vanderbilt University, Medical Center, Nashville, Tennessee 37232 6307, USA
    Gastroenterology 128:1642-54. 2005
    ..This article will summarize the data that has led to the current standards of therapy for patients with resectable and advanced pancreatic cancer and review new treatment strategies for this disease...

Research Grants1

  1. PS-341 in Hepatocellular Carcinoma: A Phase II Trial
    Jordan Berlin; Fiscal Year: 2004
    ..abstract_text> ..